Norbormide: a calcium entry blocker with selective vasoconstrictor activity in rat peripheral arteries

Area of Science:

• Pharmacology
• Vascular Biology
• Biochemistry

Background:

• Norbormide exhibits complex, species- and tissue-specific vasoactive properties.
• It acts as a vasoconstrictor in rat peripheral arteries but a vasodilator in other species and rat aorta.
• Norbormide also demonstrates calcium channel blockade effects in guinea pig hearts and myocytes.

Purpose of the Study:

• To elucidate the mechanism behind norbormide's selective vasoconstrictor effect in rat peripheral arteries.
• To investigate the signaling pathways involved in norbormide-induced vasoconstriction.
• To identify potential therapeutic targets for tissue-selective pharmacological agents.

Main Methods:

• Vessel-based assays to assess vasoconstrictor and vasodilator activities.
• Electrophysiological studies on isolated guinea pig ventricular myocytes.
• Biochemical assays to analyze signal transduction pathways, including phospholipase C (PLC) activation.

Main Results:

• Norbormide selectively induced vasoconstriction in rat caudal artery.
• This vasoconstriction was associated with the activation of the phospholipase C (PLC) signaling cascade.
• In contrast, norbormide exhibited vasorelaxant properties in rat aorta and arteries of other species, linked to calcium channel blockade.

Conclusions:

• Norbormide-induced vasoconstriction in rat peripheral arteries is mediated by the activation of PLC.
• This effect is likely due to the activation of a PLC-coupled receptor on vascular smooth muscle cells.
• Identification of this receptor could lead to the development of novel, tissue-selective vasoactive drugs.